palmitoylethanolamide.com.au
HomeResearchVeredice 2026

Investigating Properties of Palmitoylethanolamide in Physiology and Disease: Far Beyond an Anti-Inflammatory Shield

Veredice C, Turrini I, Pelanda H, Contaldo I, Rigante D. Diseases, 2026; 14(2):52.

ReviewHumansOther animals

Design
Review
What was measured
Where palmitoylethanolamide might help beyond inflammation: mechanisms and clinical uses studied in nerve pain, migraine, neurodegenerative disease, and lung, liver, kidney, rheumatological and metabolic conditions.

What the authors reported

The authors describe wide-ranging protective effects in laboratory work and report a good tolerability record in people, with minimal risk of drug interactions. They say most of the evidence comes from laboratory studies or small trials, that dosing is inconsistent across studies, and that larger and more varied patient groups are needed.

Limits of this study

A narrative review. The authors' own list of gaps applies to the evidence it summarises. It received no external funding, and the authors declared no conflicts.

Source

doi:10.3390/diseases14020052

Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.